End-stage heart failure: which options?

  • Deng M
  • Ascheim D
  • Edwards N
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Randomized clinical trials have established the roles of angiotensin-converting enzyme inhibitors, beta-blockers, spironolactone, mechanical circulatory support devices and defibrillators in advanced heart failure. Observational data support the use of cardiac surgical interventions, including revascularization, mitral valve repair, left ventricular geometry restoration, re synchronization therapy and cardiac transplantation. The potential of gene therapy, cell transplantation and xenotransplantation is actively being explored. Comprehensive heart failure centres with expertise in all aspects of medical and surgical advanced heart failure care are evolving, and aim to translate evidence-based management protocols into effective clinical practice.

Cite

CITATION STYLE

APA

Deng, M. C., Ascheim, D. D., Edwards, N. M., & Naka, Y. (2002). End-stage heart failure: which options? European Heart Journal Supplements, 4(suppl_D), D122–D130. https://doi.org/10.1093/ehjsupp/4.suppl_d.d122

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free